Oncology Clinical Trials Market Overview
Global Oncology Clinical Trials Market reached US$ 19.73 billion in 2024 , growing at a CAGR of YY% during the forecast period 2026-2033.
The global oncology clinical trials market is undergoing a phase of renewed momentum, driven by scientific innovation, rising cancer prevalence, and sustained investment in drug development.
In 2024, oncology trial activity showed a modest resurgence with over 2,160 new trial starts, reflecting renewed confidence after recent operational slowdowns. Trial designs are increasingly focused on rare cancers and solid tumors, addressing high unmet clinical needs. Geographically, there is a clear shift toward single-country trials, with China playing a pivotal role in expanding domestic oncology research capacity. Multi-country oncology studies now represent only a small share of new trial initiations, signaling a more regionally concentrated development strategy.
Clinical trial productivity in oncology has improved by more than 50% since 2019, supported by better trial design, biomarker integration, and data analytics. Despite these gains, oncology development still faces efficiency challenges compared to other therapeutic areas due to disease complexity and patient heterogeneity.
A key growth driver is the rapid expansion of PD-1/PD-L1 inhibitors, which are increasingly used as first-line therapies and in earlier disease stages, particularly in high-income markets. This shift is broadening patient eligibility and improving long-term survival outcomes.
Investment momentum remains strong, with global cancer medicine spending reaching $252 billion in 2024 and projected to rise sharply by 2029. New drug launches, wider access, and adoption of advanced modalities such as antibody–drug conjugates and bispecific antibodies continue to fuel market expansion.
Emerging technologies are further transforming clinical trials, with AI tools, liquid biopsies, and spatial profiling improving patient selection, response prediction, and trial success rates. Looking ahead, continued technological integration, regional trial expansion, and precision oncology approaches are expected to drive sustained growth and reshape the future of the global oncology clinical trials market.
Market Scope
| Metrics | Details |
| CAGR | YY% |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Phase Type, Study Design, Cancer Type, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rising Incidence of Cancer Cases
The rising global incidence of cancer is a significant catalyst for the expansion of the oncology clinical trials market. According to the International Agency for Research on Cancer (IARC), there were nearly 20 million new cancer cases worldwide in 2022. This number is projected to increase by 77% by 2050, reaching about 35 million new cases annually.
Lung cancer remains the most commonly diagnosed, accounting for around 12.4% of all cases, followed by breast cancer at 11.6% and colorectal cancer at 9.6%. Breast cancer alone is expected to reach 3.2 million new cases annually by 2050. These rising cancer rates, fueled by aging populations, lifestyle factors, and environmental influences, create an urgent demand for improved diagnostics and treatments.
To meet this challenge, the number of oncology clinical trials has risen, with 2,162 new trials initiated in 2024, a 12% increase from 2019, focusing especially on rare cancers and solid tumors.
Clinical research organizations (CROs) play a vital role in managing these trials. There were 4,321 Contract Research Organizations in the US businesses as of 2024, an increase of 2.1% from 2023.
The expanding burden of cancer worldwide is thus directly increasing clinical trial activity, enabling researchers and healthcare providers to find new, more effective therapies that can better save and improve the lives of cancer patients globally.
Complicated conditions and targeted treatments
Cancer treatment is moving toward more targeted therapies: As researchers identify cancer molecular pathways and targets, it is becoming possible to treat the target tumour regardless of the organ of origin. More targeted therapies may change which patients and cancers may benefit, since a given treatment may only impact very specific biomarkers and genetic profiles.
Market Segment Analysis
The global oncology clinical trials market is segmented based on phase type, study design, cancer type, end user and region.
Phase III from the phase type segment accounted for approximately 43.3%. of the oncology clinical trials market share
Phase III from the phase type segment accounted for approximately 43.3%. Phase III oncology clinical trials involve rigorous testing of experimental treatments in a large patient population to confirm their effectiveness and safety. Trends in this phase include personalized medicine, focusing on biomarkers for targeted therapies, and collaboration between industry and regulatory bodies to streamline processes and expedite the translation of promising treatments from research to clinical end user.
For instance, in January 2024, Merck announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the favourable reimbursement policies, and the presence of major market players in the region, leading to investment and the development of innovative products. Also, the U.S. FDA has a fast-track approval process for drugs that treat cancer. Moreover, an increase in R&D in the area and government funding also help the region to grow during the forecast period.
For instance, in February 2024, the National Institutes of Health launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network (CSRN) will support the Biden-Harris administration’s Cancer Moonshot by investigating how to identify cancers earlier, when they may be easier to treat. Eight groups have received funding from the National Cancer Institute (NCI), part of NIH, to carry out the initial activities of the network.
Covid 19 Impact Analysis
The COVID-19 pandemic has significantly impacted oncology care and clinical trials, leaving a lasting impact on healthcare services. Despite the disruption, the response has led to innovations and adaptations that will be valuable in the future. The pandemic has helped address inefficiencies in clinical trial conduct, such as excessive bureaucracy and patient monitoring, and has driven improvements for faster and safer trials in the future.
Market Competitive Landscape
The major global players in the market include AstraZeneca, Merck & Co., Inc, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd, Syneos Health, Daiichi Sankyo Company, Eli Lilly and Company, PharmaMar, Novocure, Pfizer Inc among others.
Key Developments
- In June 2022, Novartis reported positive outcomes from the Phase III RATIONALE 306 trial, revealing that tislelizumab in combination with chemotherapy significantly enhanced overall survival (OS) as a primary treatment for adult patients dealing with unresectable, locally advanced, or metastatic oesophagal squamous cell carcinoma (ESCC), irrespective of their PD-L1 status.
- In March 2021, Merck Sharp & Dohme Corp. initiated a phase II clinical study to assess the safety and efficacy of the fixed-dose co-formulated pembrolizumab/quavonlimab (MK-1308A) in conjunction with lenvatinib for patients with hepatocellular carcinoma (HCC).
Why Purchase the Report?
- To visualise the global oncology clinical trials market segmentation based on phase type, study design, cancer type, end user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analysing trends and co-development.
- Excel data sheet with numerous data points of the oncology clinical trials market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global oncology clinical trials market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
